NasdaqGS:TSHABiotechs
Taysha’s TSHA-102 Rett Data Links Clinical Promise To Future Revenue
Taysha Gene Therapies (NasdaqGS:TSHA) reported positive early results from the REVEAL Phase 1/2 trial of TSHA-102 in Rett syndrome, including a high responder rate and durable functional improvements.
The company highlighted a favorable safety profile for TSHA-102 and outlined upcoming milestones in 2026 related to additional clinical data, regulatory submissions, and commercial manufacturing preparation.
Taysha Gene Therapies, trading around $5.71, is drawing attention as TSHA-102 advances...